Aprea Therapeutics (NASDAQ:APRE) Stock Rated “Buy” in New Coverage at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Aprea Therapeutics (NASDAQ:APRE) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $2.00 target price on the stock.

Other analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Wedbush dropped their price target on Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $2.80.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $0.58 on Wednesday. The business’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.76. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.69.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.11. Analysts predict that Aprea Therapeutics will post -0.36 earnings per share for the current year.

Institutional Trading of Aprea Therapeutics

A hedge fund recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC lifted its position in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,015,541 shares of the company’s stock after purchasing an additional 645,000 shares during the quarter. AIGH Capital Management LLC owned about 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.